Krsnaa Diagnostics Receives In-Principle Approval for Preferential Convertible Warrants Issue
Krsnaa Diagnostics Ltd 路 Others (Uncategorized) 路 09 Oct 2026, 3:11 am
Krsnaa Diagnostics Receives In-Principle Approval for Preferential Convertible Warrants Issue Krsnaa Diagnostics Limited received in-principle approval from BSE and NSE on 8th Oct'26 to issue 16,21,000 convertible warrants on a preferential basis to its Promoter and Promoter Group under Regulation 28(1) of SEBI LODR. Each warrant is convertible into one equity share of face value Rs. 5 each at an issue price of Rs. 566 per share, aggregating to approximately Rs. 91.75 crore. A rectified approval letter from BSE will be submitted separately due to factual errors in the initial communication.
Original exchange filing (PDF)
More announcements from Krsnaa Diagnostics Ltd
- Earnings Call Transcript for quarter and half year ended September 30, 2026 路 08 Nov 2026
- Intimation of Change in Corporate office of Registrar and Sahre Trasnfer Agent of the Company w.e.f. 1st December 2026. 路 04 Nov 2026
- Audio recording of conference call for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Submission of Certificate obtained from Statutory Auditors in terms of Regulation 169(5) of the SEBI ICDR Regulations, 2018 路 03 Nov 2026
- Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015 - Krsnaa Diagnostics secures 15 year Cash based PPP project from Municipal corporation of Delhi for Advanced CT Scan and .... 路 03 Nov 2026
- Investor Presentation for the Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026 路 03 Nov 2026
- Press Release - Unaudited Financial Results (Standalone and Consolidated) for the Quarter and Half year ended September 30, 2026 路 03 Nov 2026
- Financial Results for Quarter and Half Year ended September 30, 2026 路 02 Nov 2026
